Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-11-21, Stock:LLY, The news for the past five days is as follows:
2018-11-14: NEWS1: AbbVie's HCV Drug Mavyret Succeeds in Label Expansion Study.NEWS2: AbbVie's HCV Drug Mavyret Succeeds in Label Expansion Study.NEWS3: Migraine-Focused Biotech Has A Headache On Quarterly Losses.NEWS4: AbbVie&apos;s HCV Drug Mavyret Succeeds in Label Expansion Study.NEWS5: Merck Starts Rolling BLA Submission for Ebola Vaccine V920.NEWS6: Merck Starts Rolling BLA Submission for Ebola Vaccine V920.NEWS7: Merck Starts Rolling BLA Submission for Ebola Vaccine V920.NEWS8: Shire's Filing Accepted by FDA for Gattex's Label Expansion.NEWS9: Shire's Filing Accepted by FDA for Gattex's Label Expansion.NEWS10: Shire&apos;s Filing Accepted by FDA for Gattex&apos;s Label Expansion.NEWS11: Eli Lilly announces progress on new headache medications.NEWS12: Lilly Submits New Drug Application to the FDA for Lasmiditan for Acute Treatment of Migraine, Receives Breakthrough Therapy Designation for Emgality™ (galcanezumab-gnlm) for Prevention of Episodic Cluster Headache.
2018-11-15: NEWS1: Mallinckrodt Gets FDA Committee Vote for Abuse-Deterrent Drug.NEWS2: Mallinckrodt Gets FDA Committee Vote for Abuse-Deterrent Drug.NEWS3: Mallinckrodt Gets FDA Committee Vote for Abuse-Deterrent Drug.NEWS4: Exploring Clovis Oncology’s Operational Performance.NEWS5: Understanding Clovis Oncology’s Gross Margin Trend.NEWS6: Lilly Offers Updates on Progress of Headache Disorder Drugs.NEWS7: Lilly Offers Updates on Progress of Headache Disorder Drugs.NEWS8: Lilly Offers Updates on Progress of Headache Disorder Drugs.NEWS9: Exelixis, Ipsen Get EU Nod for Label Expansion of Cabometyx.NEWS10: Exelixis, Ipsen Get EU Nod for Label Expansion of Cabometyx.NEWS11: Exelixis, Ipsen Get EU Nod for Label Expansion of Cabometyx.
2018-11-16: NEWS1: Top Stocks: IBD Screens Uncover Emerging Leaders Before Big Moves.NEWS2: Interesting LLY Put And Call Options For February 2019.NEWS3: Interesting LLY Put And Call Options For February 2019.NEWS4: Noteworthy ETF Outflows: SPYG, AMGN, TMO, LLY.NEWS5: Noteworthy ETF Outflows: SPYG, AMGN, TMO, LLY.NEWS6: Seattle Genetics' Adcetris Gets Breakthrough Therapy Status.NEWS7: Seattle Genetics' Adcetris Gets Breakthrough Therapy Status.NEWS8: Gauging Analysts’ Views on Clovis Stock.NEWS9: Eli Lilly considers sale of off-patent drug assets in China - Bloomberg.NEWS10: Pharma Stock Roundup: FDA Updates on MRK, AZN&apos;s Cancer Drugs, Bayer&apos;s Q3 Earnings.NEWS11: Seattle Genetics&apos; Adcetris Gets Breakthrough Therapy Status.NEWS12: Eli Lilly considers sale of off-patent drug assets in China - Bloomberg.NEWS13: Eli Lilly Considers Sale of China Assets to Raise Cash.
2018-11-19: NEWS1: Eli Lilly (LLY) Gains As Market Dips: What You Should Know.NEWS2: 3 Steady Healthcare Stocks to Hold During a Downturn.
2018-11-20: NEWS1: Corcept Initiates Phase III Study for Cushing's Syndrome.NEWS2: Corcept Initiates Phase III Study for Cushing's Syndrome.NEWS3: Corcept Initiates Phase III Study for Cushing's Syndrome.NEWS4: Analyzing Eli Lilly’s Stock Price and Financial Performance.NEWS5: See what the IHS Markit Score report has to say about Eli Lilly and Co..NEWS6: Eli Lilly (LLY) Gains As Market Dips: What You Should Know.NEWS7: Eli Lilly (LLY) Gains As Market Dips: What You Should Know.NEWS8: 3 Steady Healthcare Stocks to Hold During a Downturn.NEWS9: 3 Steady Healthcare Stocks to Hold During a Downturn.

Answer: Decrease